(Reuters) -Drugmaker AstraZeneca lifted its annual sales and ... The new investments will expand manufacturing sites in Maryland, Texas and California and create 1,000 high-skilled jobs in the ...
AstraZeneca has announced a major expansion ... spend $2bn to bolster its manufacturing capacity in states including Maryland and Texas as well as on the west coast. This would bring its total ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in ...
The new investments will expand manufacturing sites in Maryland, Texas and California. But AstraZeneca shares have fallen nearly 6% this year, underperforming a near 9% rise in the wider European ...
AstraZeneca made headlines for several reasons on Tuesday ... The investment will also support creation of a new next generation manufacturing facility, focused on biologics, in Maryland as well as ...
AstraZeneca has upgraded its annual guidance ... centre in Massachusetts and a manufacturing facility for biologics in Maryland. Soriot said the investment reflects the 'attractiveness of the ...
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L ... a next generation manufacturing facility for biologics in Maryland; Cell therapy manufacturing capacity on the West and East Coasts ...
many of the projects AstraZeneca outlined are, in fact, not exactly new. For instance, the company announced plans for its cell therapy facility in Rockville, Maryland back in February.
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; A next generation manufacturing facility for biologics in ...